Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Wake Forest University Health Sciences
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT05703269
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhibitor (ICI) therapy. This study will compare the usual care treatment of single fraction stereotactic radiosurgery (SSRS) given on one day versus fractionated stereotactic radiosurgery (FSRS), which is a lower dose of radiation given over a few days to determine if FSRS is better or worse at reducing side effects than usual care treatment.
Intervention
fractionated stereotactic radiosurgery (FSRS), single fraction stereotactic radiosurgery (SSRS)
Condition
NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma, Brain Metastases, Adult, Non-small Cell Lung Cancer, SCLC, Small-cell Lung Cancer
Investigators
Christina K Cramer, MD, Justin Tang, Andrew Huang, Bryan A Faller, Samir Narayan, Andrew J Huang, Jay W Carlson, Jeremy M Kilburn, Joana S Emmolo, Heyoung L McBride, Christina K Cramer, Bryan Faller, Jay Carlson, , Roshan Prabhu, Daniel Alquist, Daniel Almquist, Daniel Almquish, William Wilson